Thank you This live web event has ended. Thank you for attending. Contributors Michael B. Bolger, Ph.D. Professor Bolger is Chief Scientist at Simulations Plus, Inc. in Lancaster, CA. His formal education has been in Biology, Chemistry, Pharmaceutical Sciences, and Pharmacology at UC San Diego and UC San Francisco. He was a professor of Pharmaceutical Sciences for 23 years at the University of Southern California School of Pharmacy and retired from USC in 2004. During this period he developed an interest in the computational aspects of drug design and drug development. From 1987-1993 he was a founder and Director of Medicinal Chemistry at CoCensys Inc. There, he studied the chemistry and use of novel neuroactive steroids for treatment of anxiety, epilepsy, and sleep disorders. Drug candidates emanating from seven of Dr. Bolger’s patents have been tested in Phase I and II clinical trials for petite mal epilepsy, sleep disorders, and migraine. Dr. Bolger programmed the first version of GastroPlus in 1997 and for the last 20 years has worked with a team of scientist / programmers at Simulations Plus, Inc. (Lancaster, CA) in the development of software programs for estimation of biopharmaceutical properties and simulations of absorption and bioavailability. He was elected to the rank of Fellow of the American Association for the Advancement of Science in 1996. David B. Turner, Ph.D. Dr. Turner is a Principle Scientist at Simcyp Limited located in Sheffield, UK with lead responsibility for the oral absorption modelling team. His first degree was in Biochemistry after which he obtained an MSc in Computer Science. He obtained his PhD in 1996 from Sheffield University in Cheminformatics and QSAR Modelling. Subsequently, he worked as a Postdoctoral Researcher in the same group for several years developing spectral descriptors for QSAR modeling and molecular similarity scoring. From 1999 he spent three years in the Computational Drug Discovery Group at Synt:em SA, a biopharmaceutical company based in Nîmes, France, involved mainly in early discovery virtual screening projects. He joined Simcyp Limited in late 2004 where his main responsibilities currently lie with the physico-chemical aspects of the development of the Simcyp Population-based ADME Simulator particularly the PBPK oral absorption and tissue distribution models and QSAR model development. He is currently Principal Investigator on a two-year US FDA funded grant for the development of PBPK Modeling tools for Supersaturating Drug Products.